UCB (OTCMKTS:UCBJF) Stock Price Down 6.2% – Here’s Why

Shares of UCB SA (OTCMKTS:UCBJF) dropped 6.2% during mid-day trading on Friday . The stock traded as low as $284.3501 and last traded at $284.3501. Approximately 6 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 698 shares. The stock had previously closed at $303.29.

Analyst Ratings Changes

A number of brokerages have weighed in on UCBJF. Wolfe Research initiated coverage on UCB in a report on Monday, February 23rd. They set an “outperform” rating for the company. Barclays reiterated an “overweight” rating on shares of UCB in a report on Tuesday, January 6th. Stephens restated an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of UCB in a research report on Monday, December 8th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a report on Monday, February 16th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy”.

UCB Trading Down 6.2%

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The company’s 50-day moving average is $311.36 and its two-hundred day moving average is $285.34.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.